Literature DB >> 8340706

Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis.

A V Panyutich1, E A Panyutich, V A Krapivin, E A Baturevich, T Ganz.   

Abstract

We measured concentrations of defensins (human neutrophil peptides) in the plasma of healthy volunteers and patients with sepsis and meningitis. When a sensitive enzyme immunoassay was used, defensins were detected in plasma samples from 13 of 24 healthy blood donors, with a mean +/- SD of 42 +/- 53 ng/ml. Defensin levels in plasma samples from seven patients with sepsis at the onset of disease ranged from 900 ng/ml to 170,000 ng/ml. In 10 patients with meningitis in the initial phase of disease, plasma defensin concentrations ranged from 120 ng/ml to 910 ng/ml. Defensin concentrations in the plasma of both patient groups were significantly higher than those in healthy blood donors (p << 0.01), and patients with sepsis had higher defensin levels than patients with meningitis (p < 0.01). Defensin levels were significantly (p < 0.01) lower after the beginning of specific antibiotic therapy. Defensin concentrations in the plasma of patients with sepsis and meningitis correlated only weakly (r = 0.38) with blood neutrophil count. In vitro studies of defensin added to plasma indicated that all defensin was bound to plasma proteins. At high concentrations (1000 micrograms/ml), defensins caused precipitation of plasma proteins. Because plasma defensin levels may reflect neutrophil activation at sites of infection and inflammation, studies of the clinical utility of defensin ELISA are indicated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8340706

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  61 in total

1.  Dynamic changes in neutrophil defensins during endotoxemia.

Authors:  M E Klut; B A Whalen; J C Hogg
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

Review 2.  Antimicrobial peptides: current status and therapeutic potential.

Authors:  Andreas R Koczulla; Robert Bals
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Roles of antimicrobial peptides such as defensins in innate and adaptive immunity.

Authors:  J J Oppenheim; A Biragyn; L W Kwak; D Yang
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

4.  Macrocyclic θ-defensins suppress tumor necrosis factor-α (TNF-α) shedding by inhibition of TNF-α-converting enzyme.

Authors:  Justin B Schaal; Thorsten Maretzky; Dat Q Tran; Patti A Tran; Prasad Tongaonkar; Carl P Blobel; André J Ouellette; Michael E Selsted
Journal:  J Biol Chem       Date:  2018-01-09       Impact factor: 5.157

5.  Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity.

Authors:  Theresa L Chang; Jesus Vargas; Armando DelPortillo; Mary E Klotman
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

6.  Defensins and other antimicrobial peptides at the ocular surface.

Authors:  Alison M McDermott
Journal:  Ocul Surf       Date:  2004-10       Impact factor: 5.033

7.  Human alpha-defensins block papillomavirus infection.

Authors:  Christopher B Buck; Patricia M Day; Cynthia D Thompson; Jacek Lubkowski; Wuyuan Lu; Douglas R Lowy; John T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

8.  Human neutrophil peptides mediate endothelial-monocyte interaction, foam cell formation, and platelet activation.

Authors:  Kieran L Quinn; Melanie Henriques; Arata Tabuchi; Bing Han; Hong Yang; Wei-Erh Cheng; Soumitra Tole; Hanpo Yu; Alice Luo; Emmanuel Charbonney; Elizabeth Tullis; Alan Lazarus; Lisa A Robinson; Heyu Ni; Blake R Peterson; Wolfgang M Kuebler; Arthur S Slutsky; Haibo Zhang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-08-04       Impact factor: 8.311

9.  Comprehensive defensin assay for saliva.

Authors:  Michael S Gardner; Megan D Rowland; Amy Y Siu; Jonathan L Bundy; Diane K Wagener; James L Stephenson
Journal:  Anal Chem       Date:  2009-01-15       Impact factor: 6.986

10.  Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura.

Authors:  Wenjing Cao; Huy P Pham; Lance A Williams; Jenny McDaniel; Rance C Siniard; Robin G Lorenz; Marisa B Marques; X Long Zheng
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.